Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Mesothelioma HELP
Based on 4,700 articles published since 2007
||||

These are the 4700 published articles about Mesothelioma that originated from Worldwide during 2007-2018.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. 2018

Husain, Aliya Noor / Colby, Thomas V / Ordóñez, Nelson G / Allen, Timothy Craig / Attanoos, Richard Luther / Beasley, Mary Beth / Butnor, Kelly Jo / Chirieac, Lucian R / Churg, Andrew M / Dacic, Sanja / Galateau-Sallé, Françoise / Gibbs, Allen / Gown, Allen M / Krausz, Thomas / Litzky, Leslie Anne / Marchevsky, Alberto / Nicholson, Andrew G / Roggli, Victor Louis / Sharma, Anupama K / Travis, William D / Walts, Ann E / Wick, Mark R. ·From the Department of Pathology, University of Chicago Medical Center, Chicago, Illinois (Drs Husain and Krausz); the Department of Laboratory Medicine and Pathology, Mayo Clinic, Scottsdale, Arizona (Dr Colby, emeritus); the Department of Pathology, University of Texas, MD Anderson Cancer Center, Houston (Dr Ordóñez); the Department of Pathology, University of Texas Medical Branch, Galveston (Dr Allen); the Department of Cellular Pathology, University Hospital of Wales and Cardiff University, Cardiff, South Glamorgan, Wales (Dr Attanoos); the Department of Pathology, Mount Sinai Medical Center, New York, New York (Dr Beasley); the Department of Pathology, University of Vermont College of Medicine, Burlington (Dr Butnor); the Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts (Dr Chirieac); the Department of Pathology, Vancouver General Hospital, Vancouver, British Columbia, Canada (Dr Churg); the Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (Dr Dacic); Centre National Référent MESOPATH Departement de Biopathologie, Lyon Cedex, France (Dr Galateau-Sallé); the Department of Pathology, University Hospital of Wales, Penarth, South Glamorgan, Wales (Dr Gibbs); the Department of Pathology, PhenoPath Laboratories, Seattle, Washington (Dr Gown); the Department of Pathology & Laboratory Medicine, University of Pennsylvania Medical Center, Philadelphia, (Dr Litzky); the Department of Pathology & Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, California (Drs Marchevsky and Walts); the Department of Histopathology, Royal Brompton & Harefield National Health Service Foundation Trust and the National Heart and Lung Institute, Imperial College, Chelsea, London, England (Dr Nicholson); the Department of Pathology, Duke University Medical Center, Durham, North Carolina (Dr Roggli); the Department of Pathology, University of Pittsburgh, and the VA Pittsburgh Healthcare System, Pittsburgh, Pennsylvania (Dr Sharma); the Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York (Dr Travis); and the Department of Pathology, University of Virginia Medical Center, Charlottesville (Dr Wick). ·Arch Pathol Lab Med · Pubmed #28686500.

ABSTRACT: CONTEXT: - Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: - To provide updated, practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: - Pathologists involved in the International Mesothelioma Interest Group and others with an interest and expertise in the field contributed to this update. Reference material included up-to-date, peer-reviewed publications and textbooks. CONCLUSIONS: - There was discussion and consensus opinion regarding guidelines for (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) recognition of the key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid MM, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels employed is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Depending on the morphology, immunohistochemical panels should contain both positive and negative markers for mesothelial differentiation and for lesions considered in the differential diagnosis. Immunohistochemical markers should have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic and membranous markers). Selected molecular markers are now being used to distinguish benign from malignant mesothelial proliferations. These guidelines are meant to be a practical diagnostic reference for the pathologist; however, some new pathologic predictors of prognosis and response to therapy are also included.

2 Guideline A proposal of Brazilian Society of Surgical Oncology (BSSO/SBCO) for standardizing cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) procedures in Brazil: pseudomixoma peritonei, appendiceal tumors and malignant peritoneal mesothelioma 2017

Batista, Thales Paulo / Sarmento, Bruno José Queiroz / Loureiro, Janina Ferreira / Petruzziello, Andrea / Lopes, Ademar / Santos, Cassio Cortez / Quadros, Cláudio de Almeida / Akaishi, Eduardo Hiroshi / Cordeiro, Eduardo Zanella / Coimbra, Felipe José Fernández / Laporte, Gustavo Andreazza / Castro, Leonaldson Santos / Batista, Ranyell Matheus Spencer Sobreira / Aguiar, Samuel / Costa, Wilson Luiz / Ferreira, Fábio Oliveira / Anonymous1011212. ·- Medicina Integral Professor Fernando Figueira Institute, Department of Surgery / Oncology, Recife, PE, Brazil. · - University of Pernambuco, Department of Surgery, Recife, PE, Brazil. · - Hospital de Base of the Federal District, Service of Surgical Oncology, Brasília, DF, Brazil. · - Complexo Hospitalar de Niterói, Service of Surgical Oncology, Niterói, RJ, Brazil. · - Marcelino Champagnat Hospital, Department of Surgical Oncology, Curitiba, PR, Brazil. · - AC Camargo Cancer Center, Department of Abdominal Surgery, São Paulo, SP, Brazil. · - AC Camargo Cancer Center, Department of Pelvic Surgery, São Paulo, SP, Brazil. · - Hospital Geral de Fortaleza, Department of Surgery, Fortaleza, CE, Brazil. · - São Rafael Hospital, Service of Surgical Oncology, Salvador, BA, Brazil. · - Hospital das Clínicas, University of São Paulo, Department of Surgical Oncology, São Paulo, SP, Brazil. · - Hospital de Caridade, Department of Surgery, Florianópolis, SC, Brazil. · - Santa Casa de Misericórdia de Porto Alegre, Department of Surgical Oncology, Porto Alegre, RS, Brazil. · - Nacional Cancer Institute, Service of Abdomino-Pelvic Surgery, Rio de Janeiro, RJ, Brazil. ·Rev Col Bras Cir · Pubmed #29019584.

ABSTRACT: Cytoreductive surgery plus hypertermic intraperitoneal chemotherapy has emerged as a major comprehensive treatment of peritoneal malignancies and is currently the standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome as well as malignant peritoneal mesothelioma. Unfortunately, there are some worldwide variations of the cytoreductive surgery and hypertermic intraperitoneal chemotherapy techniques since no single technique has so far demonstrated its superiority over the others. Therefore, standardization of practices might enhance better comparisons between outcomes. In these settings, the Brazilian Society of Surgical Oncology considered it important to present a proposal for standardizing cytoreductive surgery plus hypertermic intraperitoneal chemotherapy procedures in Brazil, with a special focus on producing homogeneous data for the developing Brazilian register for peritoneal surface malignancies.

3 Guideline Recommendations for the Diagnosis and Management of Asbestos-Related Pleural and Pulmonary Disease. 2017

Diego Roza, Carmen / Cruz Carmona, M Jesús / Fernández Álvarez, Ramón / Ferrer Sancho, Jaume / Marín Martínez, Belén / Martínez González, Cristina / Rodríguez Portal, José Antonio / Romero Valero, Fernando / Villena Garrido, Victoria. ·Complexo Hospitalario Universitario de Ferrol, La Coruña, España. Electronic address: Carmen.diego.roza@sergas.es. · Hospital Val d'Hebrón, Barcelona, España. · Hospital Universitario Central de Asturias, Oviedo, España. · Complejo Hospitalario de Navarra, Pamplona, España. · Hospital Universitario Virgen del Rocío, Sevilla, España. · Hospital Universitario Puerta del Mar, Cádiz, España. · Hospital Universitario 12 de Octubre, Madrid, España. ·Arch Bronconeumol · Pubmed #28279517.

ABSTRACT: Asbestos is the term used for a set of mineral silicates that tend to break up into fibers. Its use has been associated with numerous diseases affecting the lung and pleura in particular, all of which are characterized by their long period of latency. Asbestos, moreover, has been recognized by the WHO as a Group IA carcinogen since 1987 and its use was banned in Spain in 2002. The publication in 2013 of the 3rd edition of the specific asbestos health monitoring protocol, together with the development of new diagnostic techniques, prompted the SEPAR EROM group to sponsor publication of guidelines, which review the clinical, radiological and functional aspects of the different asbestos-related diseases. Recommendations have also been made for the diagnosis and follow-up of exposed patients. These recommendations were drawn up in accordance with the GRADE classification system.

4 Guideline Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: a secondary publication. 2015

Hjerpe, A / Ascoli, V / Bedrossian, C W M / Boon, M E / Creaney, J / Davidson, B / Dejmek, A / Dobra, K / Fassina, A / Field, A / Firat, P / Kamei, T / Kobayashi, T / Michael, C W / Önder, S / Segal, A / Vielh, P. ·Division of Clinical Pathology/Cytology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden. · Department of Radiological, Oncological and Pathological Sciences, Sapienza University, Rome, Italy. · Rush University Medical College, Chicago, IL, USA. · Leiden Cytology and Pathology Laboratory, Lieveren, The Netherlands. · National Centre for Asbestos Related Disease, School of Medicine and Pharmacology, University of Western Australia, QEII Medical Centre, Perth, WA, Australia. · Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. · Department of Laboratory Medicine in Malmö, Lund University, Malmö University Hospital, Malmö, Sweden. · Department of Medicine, University of Padova, Padova, Italy. · Department of Anatomical Pathology, St Vincents Hospital, Sydney, NSW, Australia. · Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey. · Division of Pathology, Yamaguchi Grand Medical Center, Hofu, Japan. · Cancer Education and Research Center, Osaka University Graduate School of Medicine, Osaka, Japan. · Department of Pathology, Case Western Reserve University/University Hospitals Case Medical Center, Cleveland, OH, USA. · Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. · Department of Tissue Pathology, PathWest Laboratory Medicine WA, QE2 Medical Centre, Perth, WA, Australia. · Department of Biopathology, Gustave Roussy Comprehensive Cancer Center, Villejuif, France. ·Cytopathology · Pubmed #26052757.

ABSTRACT: OBJECTIVE: To provide practical guidelines for the cytopathologic diagnosis of malignant mesothelioma. DATA SOURCES: Cytopathologists with an interest in the field involved in the International Mesothelioma Interest Group (IMIG) and the International Academy of Cytology (IAC) contributed to this update. Reference material includes peer-reviewed publications and textbooks. RATIONALE: This article is the result of discussions during and after the IMIG 2012 conference in Boston, followed by thorough discussions during the 2013 IAC meeting in Paris. Additional contributions have been obtained from cytopathologists and scientists who could not attend these meetings, with final discussions and input during the IMIG 2014 conference in Cape Town.

5 Guideline Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology. 2015

Hjerpe, Anders / Ascoli, Valeria / Bedrossian, Carlos W M / Boon, Mathilde E / Creaney, Jenette / Davidson, Ben / Dejmek, Annika / Dobra, Katalin / Fassina, Ambrogio / Field, Andrew / Firat, Pinar / Kamei, Toshiaki / Kobayashi, Tadao / Michael, Claire W / Önder, Sevgen / Segal, Amanda / Vielh, Philippe / Anonymous4240825 / Anonymous4250825 / Anonymous4260825. ·Division of Clinical Pathology/Cytology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Huddinge, Sweden. ·Acta Cytol · Pubmed #25824655.

ABSTRACT: OBJECTIVE: To provide practical guidelines for the cytopathologic diagnosis of malignant mesothelioma. DATA SOURCES: Cytopathologists with an interest in the field involved in the International Mesothelioma Interest Group (IMIG) and the International Academy of Cytology (IAC) contributed to this update. Reference material includes peer-reviewed publications and textbooks. RATIONALE: This article is the result of discussions during and after the IMIG 2012 conference in Boston, followed by thorough discussions during the 2013 IAC meeting in Paris. Additional contributions have been obtained from cytopathologists and scientists who could not attend these meetings, with final discussions and input during the IMIG 2014 conference in Cape Town.

6 Guideline Asbestos, asbestosis, and cancer, the Helsinki criteria for diagnosis and attribution 2014: recommendations. 2015

Wolff, Henrik / Vehmas, Tapio / Oksa, Panu / Rantanen, Jorma / Vainio, Harri. ·Finnish Institute of Occupational Health (FIOH) Topeliuksenkatu 41aA 00250 Helsinki Finland. Henrik.Wolff@ttl.fi. ·Scand J Work Environ Health · Pubmed #25299403.

ABSTRACT: -- No abstract --

7 Guideline Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. 2013

Husain, Aliya N / Colby, Thomas / Ordonez, Nelson / Krausz, Thomas / Attanoos, Richard / Beasley, Mary Beth / Borczuk, Alain C / Butnor, Kelly / Cagle, Philip T / Chirieac, Lucian R / Churg, Andrew / Dacic, Sanja / Fraire, Armando / Galateau-Salle, Francoise / Gibbs, Allen / Gown, Allen / Hammar, Samuel / Litzky, Leslie / Marchevsky, Alberto M / Nicholson, Andrew G / Roggli, Victor / Travis, William D / Wick, Mark / Anonymous2790735. ·Department of Pathology, University of Chicago, Chicago, IL 60637, USA. aliya.husain@uchospitals.edu ·Arch Pathol Lab Med · Pubmed #22929121.

ABSTRACT: CONTEXT: Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: To provide updated practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: Pathologists involved in the International Mesothelioma Interest Group and others with an interest in the field contributed to this update. Reference material includes peer-reviewed publications and textbooks. CONCLUSIONS: There was consensus opinion regarding (1) distinction of benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiation of epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas, and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. It is recommended that immunohistochemical markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.

8 Guideline Malignant pleural mesothelioma. 2012

Ettinger, David S / Akerley, Wallace / Borghaei, Hossein / Chang, Andrew / Cheney, Richard T / Chirieac, Lucian R / D'Amico, Thomas A / Demmy, Todd L / Ganti, Apar Kishor P / Govindan, Ramaswamy / Grannis, Frederic W / Horn, Leora / Jahan, Thierry M / Jahanzeb, Mohammad / Kessinger, Anne / Komaki, Ritsuko / Kong, Feng-Ming Spring / Kris, Mark G / Krug, Lee M / Lennes, Inga T / Loo, Billy W / Martins, Renato / O'Malley, Janis / Osarogiagbon, Raymond U / Otterson, Gregory A / Patel, Jyoti D / Schenck, Mary Pinder / Pisters, Katherine M / Reckamp, Karen / Riely, Gregory J / Rohren, Eric / Swanson, Scott J / Wood, Douglas E / Yang, Stephen C / Anonymous5560714. ·The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Baltimore, MD, USA. ·J Natl Compr Canc Netw · Pubmed #22223867.

ABSTRACT: -- No abstract --

9 Guideline [Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma]. 2010

Scherpereel, A / Astoul, P / Baas, P / Berghmans, T / Clayson, H / de Vuyst, P / Dienemann, H / Galateau-Salle, F / Hennequin, C / Hillerdal, G / Le Pe'choux, C / Mutti, L / Pairon, J-C / Stahel, R / van Houtte, P / van Meerbeeck, J / Waller, D / Weder, W / Anonymous280676 / Anonymous290676. ·Dept of Pulmonary and Thoracic Oncology,Hospital Calmette CHRU of Lille 59037 Lille Cedex, France. a-scherpereel@chru-lille.fr ·Zhongguo Fei Ai Za Zhi · Pubmed #20976998.

ABSTRACT: -- No abstract --

10 Guideline Malignant pleural mesothelioma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2010

Stahel, R A / Weder, W / Lievens, Y / Felip, E / Anonymous3010663. ·Clinic and Policlinic of Oncology, University Hospital of Zürich, Switzerland. ·Ann Oncol · Pubmed #20555061.

ABSTRACT: -- No abstract --

11 Guideline Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. 2010

Scherpereel, A / Astoul, P / Baas, P / Berghmans, T / Clayson, H / de Vuyst, P / Dienemann, H / Galateau-Salle, F / Hennequin, C / Hillerdal, G / Le Péchoux, C / Mutti, L / Pairon, J-C / Stahel, R / van Houtte, P / van Meerbeeck, J / Waller, D / Weder, W / Anonymous2000637. ·Dept of Pulmonary and Thoracic Oncology, Hôpital Calmette, CHRU of Lille, 59037 Lille Cedex, France. a-scherpereel@chru-lille.fr ·Eur Respir J · Pubmed #19717482.

ABSTRACT: Malignant pleural mesothelioma (MPM) is a rare tumour but with increasing incidence and a poor prognosis. In 2008, the European Respiratory Society/European Society of Thoracic Surgeons Task Force brought together experts to propose practical and up-to-dated guidelines on the management of MPM. To obtain an earlier and reliable diagnosis of MPM, the experts recommend performing thoracoscopy, except in cases of pre-operative contraindication or pleural symphysis. The standard staining procedures are insufficient in approximately 10% of cases. Therefore, we propose using specific immunohistochemistry markers on pleural biopsies. In the absence of a uniform, robust and validated staging system, we advice use of the most recent TNM based classification, and propose a three step pre-treatment assessment. Patient's performance status and histological subtype are currently the only prognostic factors of clinical importance in the management of MPM. Other potential parameters should be recorded at baseline and reported in clinical trials. MPM exhibits a high resistance to chemotherapy and only a few patients are candidates for radical surgery. New therapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach should be included in a prospective trial at a specialised centre.

12 Guideline Lung Cancer OncoGuia: surgical pathology report guidelines. 2009

Ramírez, Josep / Montero, M Angeles / Alejo, María / Lloreta, Josep / Anonymous3340647. ·Pathology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain. ·Clin Transl Oncol · Pubmed #20045788.

ABSTRACT: -- No abstract --

13 Guideline Guidelines for pathologic diagnosis of malignant mesothelioma: a consensus statement from the International Mesothelioma Interest Group. 2009

Husain, Aliya N / Colby, Thomas V / Ordóñez, Nelson G / Krausz, Thomas / Borczuk, Alain / Cagle, Philip T / Chirieac, Lucian R / Churg, Andrew / Galateau-Salle, Francoise / Gibbs, Allen R / Gown, Allen M / Hammar, Samuel P / Litzky, Leslie A / Roggli, Victor L / Travis, William D / Wick, Mark R. ·Department of Pathology, University of Chicago, Chicago, IL 60631, USA. ahusain@bsd.uchicago.edu ·Arch Pathol Lab Med · Pubmed #19653732.

ABSTRACT: CONTEXT: Malignant mesothelioma (MM) is an uncommon tumor that can be difficult to diagnose. OBJECTIVE: To develop practical guidelines for the pathologic diagnosis of MM. DATA SOURCES: A pathology panel was convened at the International Mesothelioma Interest Group biennial meeting (October 2006). Pathologists with an interest in the field also contributed after the meeting. CONCLUSIONS: There was consensus opinion regarding (1) distinguishing benign from malignant mesothelial proliferations (both epithelioid and spindle cell lesions), (2) cytologic diagnosis of MM, (3) key histologic features of pleural and peritoneal MM, (4) use of histochemical and immunohistochemical stains in the diagnosis and differential diagnosis of MM, (5) differentiating epithelioid MM from various carcinomas (lung, breast, ovarian, and colonic adenocarcinomas and squamous cell and renal cell carcinomas), (6) diagnosis of sarcomatoid mesothelioma, (7) use of molecular markers in the differential diagnosis of MM, (8) electron microscopy in the diagnosis of MM, and (9) some caveats and pitfalls in the diagnosis of MM. Immunohistochemical panels are integral to the diagnosis of MM, but the exact makeup of panels used is dependent on the differential diagnosis and on the antibodies available in a given laboratory. Immunohistochemical panels should contain both positive and negative markers. The International Mesothelioma Interest Group recommends that markers have either sensitivity or specificity greater than 80% for the lesions in question. Interpretation of positivity generally should take into account the localization of the stain (eg, nuclear versus cytoplasmic) and the percentage of cells staining (>10% is suggested for cytoplasmic membranous markers). These guidelines are meant to be a practical reference for the pathologist.

14 Guideline Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2008

Stahel, R A / Weder, W / Felip, E / Anonymous3550598. ·Clinic and Policlinic of Oncology, University Hospital of Zürich, Switzerland. ·Ann Oncol · Pubmed #18456764.

ABSTRACT: -- No abstract --

15 Guideline Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma. 2007

Marchevsky, Alberto M / Wick, Mark R. ·Department of Pathology and Laboratory Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA. marchevsky@cshs.org ·Appl Immunohistochem Mol Morphol · Pubmed #17525624.

ABSTRACT: There are no firmly established guidelines for the use of antibodies in immunohistology as individual tests or panels. Practicing pathologists must rely on information available in individual publications, review articles, books, and internet-based databases to develop diagnostic immunohistochemical algorithms for their individual practices. In contrast, other medical specialties have crafted many evidence-based practice guidelines (EBG) that are widely used; these have helped to augment standardization and cost effectiveness. In particular, the use of several "epithelial" and "mesothelial" antibodies has been proposed to distinguish epithelioid malignant mesothelioma from metastatic pulmonary adenocarcinoma. Other authors have previously done systematic literature reviews of this subject up through 2004 and integrated the results of 88 publications into summarized test-performance values for 15 preselected immunohistochemical markers. The results suggested that 7 tests provide optimal sensitivity and specificity (MOC-31, BG8, CEA, TTF-1, CK5/6, WT-1, and HBME-1), but they provide no guidance for integration of such data into EBG. Odds ratios (ORs) were employed to compare the effectiveness of any single test, and chosen combinations thereof, in the differential diagnosis of malignant mesothelioma and metastatic pulmonary adenocarcinoma. Surprisingly, selected single immunostains or antibody pairs yielded ORs (varying from 96.34 to 1233.19) that were equal or better in efficacy when compared with more comprehensive panels. These results support the potential value of systematic reviews, meta-analysis, and OR calculations for development of EBG in diagnostic immunohistology.

16 Guideline Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up. 2007

Anonymous5540567 / Manegold, C. · ·Ann Oncol · Pubmed #17491037.

ABSTRACT: -- No abstract --

17 Guideline Recommendations for the reporting of pleural mesothelioma. 2007

Butnor, Kelly J / Sporn, Thomas A / Ordonez, Nelson G / Anonymous1820561. ·Department of Pathology, University of Vermont, 111 Colchester Avenue, Burlington, VT 05401, USA. kelly.butnor@vtmednet.org ·Hum Pathol · Pubmed #17276491.

ABSTRACT: It has been evident for decades that pathology reports are very variable even within a single institution. Standardization of reporting is the optimal way to ensure that information necessary for patient management, prognostic and predictive factor assessment, grading, staging, analysis of outcomes, and tumor registries is included in pathology reports. In recent years, 2 societies (first the Association of Directors of Anatomic and Surgical Pathology [ADASP] and then the College of American Pathologists [CAP]) have undertaken to publish guidelines for the reporting of common cancers. The CAP assigned multidisciplinary groups of pathologists, surgeons, radiation, and medical oncologists to develop the protocols. Other pathologists and clinicians then reviewed them. After those reviews the protocols were reviewed by multiple CAP committees and finally approved by the Board of Governors. The ADASP, in contrast, chose a pathologist expert in each filed to assemble a group from within the pathology community (with clinician input if desired) to write specific cancer protocols. These were then approved by the ADASP council and subsequently by the membership. Although both societies began the process at approximately the same time, the streamlined approach adopted by the ADASP enabled them to publish years earlier in pathology journals frequented by anatomic pathologists. Although the formats are somewhat different, the contents are essentially the same. The American College of Surgery Commission on Cancer (COC) accredits cancer centers in the United States. Recently, the COC decided to require elements, deemed as essential by the CAP, to be described in all pathology reports in their accredited cancer centers as of January 2004. Importantly, they do not require that the specific CAP protocols or synoptic reports be used. The ADASP has updated all of its protocols to comply with the COC requirements in the form of 37 uniform checklists. The checklists use the staging criteria sited in the American Joint Committee on Cancer 2002 Staging Manual (sixth edition) but include a variety of other references listed in each of the checklists. Moreover, the checklists are formatted for ease of use. They may be used as templates for uniform reporting and are designed to be compatible with voice-activated transcription. The different elements in these revised ADASP diagnostic checklists have been divided into required and optional. The term required in this context only signifies compliance with the COC guidelines. The ADASP realizes that specimens and practices vary, and it will not be possible to report these elements in every case. However, the ADASP hopes that pathologists will find these checklists to be useful in daily clinical practice, while facilitating compliance with the new COC requirements.

18 Editorial Pleural IMRT after Lung-Sparing Cytoreduction for Mesothelioma: Mature Enough to Randomize. 2017

Pass, Harvey I. ·New York University Langone Medical Center, New York, New York. Electronic address: harvey.pass@med.nyu.edu. ·J Thorac Oncol · Pubmed #28532562.

ABSTRACT: -- No abstract --

19 Editorial PD-L1 Testing for Immune Checkpoint Inhibitors in Mesothelioma: For Want of Anything Better? 2017

Lantuejoul, Sylvie / Le Stang, Nolwenn / Damiola, Francesca / Scherpereel, Arnaud / Galateau-Sallé, Francoise. ·Department of Biopathology, National referent center MESOPATH-National Clinicobiologic Databasis MESOBANK, Cancer Center of Léon Bérard, Lyon, France; UGA/INSERM U1209/CNRS 5309-Institute for Advanced Biosciences-University Grenoble Alpes, Grenoble, France. Electronic address: sylvie.lantuejoul@lyon.unicancer.fr. · Department of Biopathology-Register MESONAT, Cancer Center of Léon Bérard, Lyon, France; INSERM UMR 1086, Cancers & Preventions, University Caen Basse-Normandie, Caen, France. · Department of Biopathology, National referent center MESOPATH-National Clinicobiologic Databasis MESOBANK, Cancer Center of Léon Bérard, Lyon, France. · University Lille, CHU Lille, MESOCLIN, Lille, France. · Department of Biopathology, National referent center MESOPATH-Base National Clinicobiologic Databasis MESOBANK Register multicenter MESONAT-Sante public cancer center of Léon Bérard, Lyon, France. ·J Thorac Oncol · Pubmed #28434510.

ABSTRACT: -- No abstract --

20 Editorial Is Mesothelioma in China Rare or Misdiagnosed? 2017

John, Thomas / Russell, Prudence A / Thapa, Bibhusal. ·Olivia Newton-John Cancer Centre, Austin Hospital, Melbourne, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, Australia. Electronic address: Tom.John@onjcri.org.au. · Department of Pathology, St. Vincent's Hospital, Melbourne Australia. · Olivia Newton-John Cancer Research Institute, Melbourne, Australia. ·J Thorac Oncol · Pubmed #28343542.

ABSTRACT: -- No abstract --

21 Editorial Targeting BAP1: a new paradigm for mesothelioma. 2017

Schunselaar, L M / Zwart, W / Baas, P. ·Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address: l.schunselaar@nki.nl. · Division of Molecular Pathology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address: w.zwart@nki.nl. · Department of Thoracic Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands. Electronic address: p.baas@nki.nl. ·Lung Cancer · Pubmed #28342657.

ABSTRACT: New treatment strategies for malignant pleural mesothelioma (MPM) are important. BAP1 mutations are present in 47-67% of the MPM tumors, making this a good target for treatment. Multiple functions of BAP1 are investigated in the preclinical situation. Due to many functions of BAP1, the phenotypic effect of BAP1 is diverse. Preclinical data on inhibitors reversing these phenotypic effects are promising. However, the mechanism of BAP1 is not fully elucidated yet and further research about the mechanism and possible inhibitors is necessary.

22 Editorial Malignant pleural mesothelioma: new treatments, new hopes? 2017

Scherpereel, Arnaud. ·Pulmonary and Thoracic Oncology, CHU Lille, University of Lille, Lille, France arnaud.scherpereel@chru-lille.fr. · French National network of clinical expert centres for malignant pleural mesothelioma management (MESOCLIN). ·Eur Respir J · Pubmed #28298408.

ABSTRACT: -- No abstract --

23 Editorial Improvement of Malignant Pleural Mesothelioma Prognosis: Early Diagnosis and Multimodality Treatment. 2017

Ban, Cheng-Jun / Shi, Huan-Zhong / Zhang, Yu-Hui. ·Department of Respiratory and Critical Care Medicine, Beijing Chao-Yang Hospital, Capital Medical University, Beijing 100020; Beijing Institute of Respiratory Medicine, Beijing 100020, China. ·Chin Med J (Engl) · Pubmed #28051015.

ABSTRACT: -- No abstract --

24 Editorial [Prophylactic radiotherapy for procedure-tracts metastases in pleural mesothelioma: A phase 3 trial, "SMART"… not enough]. 2016

Brosseau, S / Naltet, C / Gounant, V / Zalcman, G. ·Service d'oncologie thoracique, CIC 1425-CLIP(2) Paris-Nord, AP-HP, hôpital Bichat-Claude-Bernard, université Paris-Diderot, 46, rue Henri-Huchard, 75018 Paris, France. · Service d'oncologie thoracique, CIC 1425-CLIP(2) Paris-Nord, AP-HP, hôpital Bichat-Claude-Bernard, université Paris-Diderot, 46, rue Henri-Huchard, 75018 Paris, France; U830 Inserm « Génétique et biologie des cancers », centre de recherche, institut Curie, 26, rue d'Ulm, 75248 Paris cedex 05, France. Electronic address: gerard.zalcman@aphp.fr. ·Rev Mal Respir · Pubmed #27968925.

ABSTRACT: -- No abstract --

25 Editorial Modulating Immunosuppression in the Intrapleural Space of Malignant Pleural Mesothelioma and Predictive Biomarkers to Guide Treatment Decisions. 2016

Wong, Raymond M. ·Pacific Mesothelioma Center, Pacific Heart, Lung and Blood Institute, Los Angeles, California. Electronic address: rwong@phlbi.org. ·J Thorac Oncol · Pubmed #27663394.

ABSTRACT: -- No abstract --

Next